Skip Navigation LinksHome > January 2013 - Volume 25 - Issue 1 > Current World Literature
Text sizing:
A
A
A
Current Opinion in Oncology:
doi: 10.1097/CCO.0b013e32835c1381
CURRENT WORLD LITERATURE: Bibliography

Current World Literature

Free Access

This bibliography is compiled by clinicians from the relevant journals scanned by this publication. It is based on the literature regularly pulled into our database from OvidSP (articles are generally added to the database about two and a half months after publication). In addition, the bibliography contains every paper annotated by reviewers; these references were obtained from a variety of bibliographic databases and published between the beginning of the review period and the time of going to press. The bibliography has been grouped into topics that relate to the reviews in this issue.

▪ Papers considered by the reviewers to be of special interest

▪▪ Papers considered by the reviewers to be of outstanding interest

The number in square brackets following a selected paper, e.g. [7], refers to its number in the annotated references of the corresponding review.

Back to Top | Article Outline
Endocrine tumors
Ultrasound elastography in the evaluation of thyroid nodules for thyroid cancer

Review: (pp. 1–5)

Aiken AH. Imaging of Thyroid Cancer. Semin Ultrasound CT MRI 2012; 33:138–149. PubMed | CrossRef

▪. Bhatia KS, Rasalkar DP, Lee YP, et al. Cystic change in thyroid nodules: a confounding factor for real-time qualitative thyroid ultrasound elastography. Clin Radiol 2011; 66:799–807. [02]

▪. Bhatia KS, Tong CS, Cho CC, et al. Shear wave elastography of thyroid nodules in routine clinical practice: preliminary observations and utility for detecting malignancy. Eur Radiol 2012. [Epub ahead of print] [21]

Kim DW, Choo HJ, Park JS, Lee EJ, et al. Ultrasonography-guided fine-needle aspiration cytology for thyroid nodules: An emphasis on one-sampling and biopsy techniques. Diagn Cytopathol 2012; 40:E48–E54. PubMed | CrossRef

▪. Kim JK, Baek JH, Lee JH, et al. Ultrasound elastography for thyroid nodules: a reliable study? Ultrasound Med Biol 2012; 38:1508–1513. [04]

▪▪. Lippolis PV, Tognini S, Materazzi G, et al. Is elastography actually useful in the presurgical selection of thyroid nodules with indeterminate cytology? J Clin Endocrinol Metab 2011; 96:E1826–1830. [08]

▪▪. Shuzhen C. Comparison analysis between conventional ultrasonography and ultrasound elastography of thyroid nodules. Eur J Radiol 2011; 81:1806–1811. [03]

Wong KK, Dvorak RA, Marzola MC, Grassetto G, et al. Molecular imaging in the management of thyroid cancer. Q J Nucl Med Mol Imag 2011; 55:541–559.

Back to Top | Article Outline
Diagnostic value of thyroglobulin assay in cervical lymph node fine-needle aspirations for metastatic differentiated thyroid cancer

Review: (pp. 6–13)

Belar O, De La Hoz C, Perez-Nanclares G, Castano L, et al. Novel mutations in MEN1, CDKN1B and AIP genes in patients with multiple endocrine neoplasia type 1 syndrome in Spain. Clin Endocrinol 2012; 76:719–724. View Full Text | PubMed | CrossRef

▪. Cappelli G, Pirola I, De Martino E, et al. Thyroglobulin measurement in fine-needle aspiration biopsy of metastatic lymph nodes after rhTSH stimulation. Head Neck 2011 doi: 10.1002/hed.21796. [34]

▪▪. Chindris AM, Diehl NN, Crook JE, et al. Undetectable sensitive serum thyroglobulin (<0.1 ng/ml) in 163 patients with follicular cell-derived thyroid cancer: results of rhTSH stimulation and neck ultrasonography and long-term biochemical and clinical follow-up. J Clin Endocrinol Metab 2012. [23]

Dustin SM, Jo VY, Hanley KZ, Stelow EB. High sensitivity and positive predictive value of fine-needle aspiration for uncommon thyroid malignancies. Diagn Cytopathol 2012; 40:416–421. PubMed | CrossRef

Kim DW, Choo HJ, Park JS, Lee EJ, et al. Ultrasonography-guided fine-needle aspiration cytology for thyroid nodules: An emphasis on one-sampling and biopsy techniques. Diagn Cytopathol 2012; 40:E48–E54. PubMed | CrossRef

▪▪. Rondeau G, Fish S, Hann LE, et al. Ultrasonographically detected small thyroid bed nodules identified after total thyroidectomy for differentiated thyroid cancer seldom show clinically significant structural progression. Thyroid 2011; 21:845–853. [29]

▪▪. Snozek CL, Chambers EP, Reading CC, et al. Serum thyroglobulin, high resolution ultrasound, and lymph node thyroglobulin in diagnosis of differentiated thyroid carcinoma nodal metastases. J Clin Endocrinol Metab 2007; 92:4278–4281. [42]

Sotos JG. Abraham Lincoln's marfanoid mother: the earliest known case of multiple endocrine neoplasia type 2B? Clin Dysmorphol 2012; 21:131–136.

Wong KK, Dvorak RA, Marzola MC, Grassetto G, et al. Molecular imaging in the management of thyroid cancer. Q J Nucl Med Mol Imag 2011; 55:541–559.

Back to Top | Article Outline
Radiofrequency and ethanol ablation for the treatment of recurrent thyroid cancers: current status and challenges

Review: (pp. 14–19)

Andreou A, Brouquet A, Bharathy KGS, Perrier ND, et al. Liver resection for liver metastases from nondigestive endocrine cancer: Extrahepatic disease burden defines outcome. Surgery 2012; 151:851–859. View Full Text | PubMed | CrossRef

▪. Baek JH, Kim YS, Sung JY, et al. Locoregional control of metastatic well differentiated thyroid cancer by ultrasound-guided radiofrequency ablation. AJR Am J Roentgenol 2011; 197:W331–336. [03]

Grabellus F, Nagarajah J, Bockisch A, Schmid KW, et al. Glucose Transporter 1 Expression, Tumor Proliferation, and Iodine/Glucose Uptake in Thyroid Cancer With Emphasis on Poorly Differentiated Thyroid Carcinoma. Clin Nucl Med 2012; 37:121–127. View Full Text | PubMed | CrossRef

▪▪. Heilo A, Sigstad E, Fagerlid KH, et al. Efficacy of ultrasound-guided percutaneous ethanol injection treatment in patients with a limited number of metastatic cervical lymph nodes from papillary thyroid carcinoma. J Clin Endocrinol Metab 2011; 96:2750–2755. [04]

▪▪. Na DG, Lee JH, Jung SL, et al. Radiofrequency ablation of benign thyroid nodules and recurrent thyroid cancers: consensus statement and recommendations. Korean J Radiol 2012; 13:117–125. [08]

▪. Park KW, Shin JH, Han BK, et al. Inoperable symptomatic recurrent thyroid cancers: preliminary result of radiofrequency ablation. Ann Surg Oncol 2011; 18:2564–2568. [02]

Polyzos SA, Kountouras J, Deretzi G, Zavos C, et al. The Emerging Role of Endocrine Disruptors in Pathogenesis of Insulin Resistance: A Concept Implicating Nonalcoholic Fatty Liver Disease. Curr Mol Med 2012; 12:68–82. PubMed | CrossRef

Schlumberger M, Chougnet C, Baudin E, Leboulleux S. Refractory thyroid cancers. Presse Med 2011; 40:1189–1198. PubMed | CrossRef

Wallace LB, Berber E. Percutaneous and Video-Assisted Ablation of Endocrine Tumors: Liver, Adrenal, and Thyroid. Surg Laparosc Endosc Pct Tech 2011; 21:255–259.

Walsh S, Prichard R, Hill ADK. Emerging therapies for thyroid carcinoma. Surg J R Coll Surg Edinb Irel 2012; 10:53–58.

Back to Top | Article Outline
Surgical management of the lateral neck compartment for metastatic thyroid cancer

Review: (pp. 20–26)

Bible KC, Foote RL, Smallridge RC. Toward Improved Outcomes in Patients With Anaplastic Thyroid Cancer. Oncology-NY 2012; 26:398–406.

Burnison CM, Lim S. Multimodal Approach to Anaplastic Thyroid Cancer. Oncology-NY 2012; 26:378–398.

Huang LC, Poultsides GA, Norton JA. Surgical Management of Neuroendocrine Tumors of the Gastrointestinal Tract. Oncology-NY 2011; 25:794–803.

Krzeslak A, Jozwiak P, Lipinska A. Down-regulation of beta-N-acetyl-D-glucosaminidase increases Akt1 activity in thyroid anaplastic cancer cells. Oncol Rep 2011; 26:743–749. PubMed

▪▪. Machens A, Dralle H. Prognostic impact of N staging in 715 medullary thyroid cancer patients: proposal for a revised staging system. Ann Surg 2012. doi: 10.1097/SLA.0b013e318268301d. [35]

▪▪. Machens A, Dralle H. Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab 2010; 95:2655–2663. [45]

Misiukiewicz K, Posner M. Time to Change the Treatment Paradigms in Anaplastic Thyroid Carcinoma. Oncology-NY 2012; 26:408–410.

Onoda N, Nakamura M, Hosono M, Sasaki Y, et al. Successful surgical treatment of advanced follicular thyroid carcinoma with tumor thrombus infiltrating the superior vena cava: report of a case. Surg Today 2012; 42:185–190. PubMed | CrossRef

▪. Park JH, Lee YS, Kim BW, et al. Skip lateral neck node metastases in papillary thyroid carcinoma. World J Surg 2012; 36:743–747. [07]

▪▪. Zhang L, Wei WJ, Ji QH, et al. Risk factors for neck metastasis in papillary thyroid carcinoma: a study of 1066 patients. J Clin Endocrinol Metab 2012; 97: 1250–1257. [08]

Back to Top | Article Outline
Management of microcarcinomas (papillary and medullary) of the thyroid

Review: (pp. 27–32)

Andreou A, Brouquet A, Bharathy KGS, Perrier ND, et al. Liver resection for liver metastases from nondigestive endocrine cancer: Extrahepatic disease burden defines outcome. Surgery 2012; 151:851–859. View Full Text | PubMed | CrossRef

Assmann G, Verdorfer I, Jung A, Bader M, et al. Dysregulation of the cell cycle and chromosomal imbalances in juxtaglomerular cell tumors - A comparative study with endocrine tumors of the pancreas. Pathol Res Pract 2011; 207:343–353. PubMed | CrossRef

Ban EJ, Andrabi A, Grodski S, Yeung M, et al. Follicular thyroid cancer: minimally invasive tumours can give rise to metastases. ANZ Journal of Surgery 2012; 82:136–139. View Full Text | PubMed | CrossRef

Feher LZ, Pocsay G, Krenacs L, Zvara A, et al. Amplification of Thymosin Beta 10 and AKAP13 Genes in Metastatic and Aggressive Papillary Thyroid Carcinomas. Pathol Oncol Res 2012; 18:449–458. PubMed | CrossRef

Halaszlaki C, Takacs I, Butz H, Patocs A, et al. Novel Genetic Mutation in the Background of Carney Complex. Pathol Oncol Res 2012; 18:149–152. PubMed | CrossRef

▪. Niemeier LA, Kuffner Akatsu H, Song C, et al. A combined molecular–pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer 2012; 118:2069–2077. [03]

Walsh S, Prichard R, Hill ADK. Emerging therapies for thyroid carcinoma. Surg J R Coll Surg Edinb Irel 2012; 10:53–58.

▪. Yu XM, Wan Y, Sippel RS, Chen H. Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases. Ann Surg 2011; 254:653–660. [12]

Back to Top | Article Outline
Aggressive variants of papillary thyroid cancer

Review: (pp. 33–38)

▪▪. Kazaure HS, Roman SA, Sosa JA. Insular thyroid cancer: a population-level analysis of patient characteristics and predictors of survival. Cancer 2012; 118:3260–3267. [18]

▪▪. Kazaure HS, Roman SA, Sosa JA. Aggressive variants of papillary thyroid cancer: incidence, characteristics and predictors of survival among 43,738 patients. Ann Surg Oncol 2012; 19:1874–1880. [08]

Kazaure HS, Roman SA, Sosa JA. Insular thyroid cancer A Population-Level Analysis of Patient Characteristics and Predictors of Survival. Cancer 2012; 118:3260–3267. PubMed | CrossRef

Landriscina M, Pannone G, Piscazzi A, Toti P, et al. Epidermal Growth Factor Receptor 1 Expression Is Upregulated in Undifferentiated Thyroid Carcinomas in Humans. Thyroid 2011; 21:1227–1234. PubMed | CrossRef

▪. Prazeres H, Torres J, Rodrigues F, et al. Chromosomal, epigenetic and microRNA-mediated inactivation of LRP1B, a modulator of the extracellular environment of thyroid cancer cells. Oncogene 2011; 30:1302–1317. [24]

▪. Virk RK, Van Dyke AL, Finkelstein A, et al. BRAF (V600E) mutation in papillary thyroid microcarcinoma: a genotype–phenotype correlation. Mod Pathol 2012 [Epub ahead of print]. [21]

▪▪. Volante M, Collini P, Nikiforov Y, et al. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol 2007; 31:1256–1264. [02]

Back to Top | Article Outline
Vandetanib and the management of advanced medullary thyroid cancer

Review: (pp. 39–43)

Andreou A, Brouquet A, Bharathy KGS, Perrier ND, et al. Liver resection for liver metastases from nondigestive endocrine cancer: Extrahepatic disease burden defines outcome. Surgery 2012; 151:851–859. View Full Text | PubMed | CrossRef

Brassard M, Neraud B, Trabado S, Salenave S, et al. Endocrine Effects of the Tyrosine Kinase Inhibitor Vandetanib in Patients Treated for Thyroid Cancer. J Clin Endocrinol Metab 2011; 96:2741–2749. View Full Text | PubMed | CrossRef

Ceolin L, Siqueira DR, Ferreira CV, Romitti M, et al. Additive effect of RET polymorphisms on sporadic medullary thyroid carcinoma susceptibility and tumor aggressiveness. Eur J Endocrinol 2012; 166:847–854. PubMed | CrossRef

▪. Degrauwe N, Sosa JA, Roman S, et al. Vandetanib for the treatment of metastatic medullary thyroid cancer. Clin Med Insights Oncol 2012; 6:243–252. [08]

Harris PJ, Bible KC. Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches. Expert Opin Investig Drugs 2011; 20:1357–1375. PubMed | CrossRef

Kaemmerer D, Prasad V, Daffner W, Haugvik SP, et al. Radioguided Surgery in Neuroendocrine Tumors Using Ga-68-Labeled Somatostatin Analogs A Pilot Study. Clin Nucl Med 2012; 37:142–147. View Full Text | PubMed | CrossRef

Kapiteijn E, Schneider TC, Morreau H, Gelderblom H, et al. New treatment modalities in advanced thyroid cancer. Ann Oncol 2012; 23:10–18. View Full Text | PubMed | CrossRef

▪. Kloos RT, Eng C, Evans DB, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association Task Force. Thyroid 2009; 19:565–612. [05]

Lerch C, Richter B. Pharmacotherapy Options for Advanced Thyroid Cancer A Systematic Review. Drugs 2012; 72:67–85. View Full Text | PubMed | CrossRef

Mosci C, Iagaru A. PET/CT Imaging of Thyroid Cancer. Clin Nucl Med 2011; 36:E180–E185. View Full Text | PubMed | CrossRef

Nabawi AS, Al Wagih HF, Hemeida MA, Koraitim TY, et al. Fungating Thyroid Cancer: A Complex Clinical Scenario. World JSurg 2012; 36:598–606.

Verburg FA, Brans B, Mottaghy FM. Molecular nuclear therapies for thyroid carcinoma. Methods 2011; 55:230–237. PubMed | CrossRef

Walsh S, Prichard R, Hill ADK. Emerging therapies for thyroid carcinoma. Surg J R Coll Surg Edinb Irel 2012; 10:53–58.

▪. Wells SA, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012; 30:134–141. [18]

Back to Top | Article Outline
New targeted therapies and other advances in the management of anaplastic thyroid cancer

Review: (pp. 44–49)

▪▪. Akaishi J, Sugino K, Kitagawa W, et al. Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma. Thyroid 2011; 21:1183–1189. [04]

Aktas B, Muller V, Tewes M, Zeitz J, et al. Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Gynecol Oncol 2011; 122:356–360. PubMed | CrossRef

Andreou A, Brouquet A, Bharathy KGS, Perrier ND, et al. Liver resection for liver metastases from nondigestive endocrine cancer: Extrahepatic disease burden defines outcome. Surgery 2012; 151:851–859. View Full Text | PubMed | CrossRef

Antonelli A, Bocci G, La Motta C, Ferrari SM, et al. CLM94, a Novel Cyclic Amide with Anti-VEGFR-2 and Antiangiogenic Properties, Is Active against Primary Anaplastic Thyroid Cancer in Vitro and in Vivo. J Clin Endocrinol Metab 2012; 97:E528–E536. View Full Text | PubMed | CrossRef

Bible KC, Foote RL, Smallridge RC. Toward Improved Outcomes in Patients With Anaplastic Thyroid Cancer. Oncology-NY 2012; 26:398–406.

▪▪. Bible KC, Suman VJ, Menefee ME, et al. A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. J Clin Endocrinol Metab 2012 [Epub ahead of print]. [18]

Burnison CM, Lim S. Multimodal Approach to Anaplastic Thyroid Cancer. Oncology-NY 2012; 26:378–398.

Capdevila J, Iglesias L, Halperin I, Segura A, et al. Sorafenib in metastatic thyroid cancer. Endocr-Relat Cancer 2012; 19:209–216. PubMed | CrossRef

Caronia LM, Phay JE, Shah MH. Role of BRAF in Thyroid Oncogenesis. Clin Cancer Res 2011; 17:7511–7517. PubMed

Catalano MG, Pugliese M, Gargantini E, Grange C, et al. Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo. Int J Cancer 2012; 130:694–704. PubMed | CrossRef

Chiappetta G, Basile A, Arra C, Califano D, et al. BAG3 Down-Modulation Reduces Anaplastic Thyroid Tumor Growth by Enhancing Proteasome-Mediated Degradation of BRAF Protein. J Clin Endocrinol Metab 2012; 97:E115–E120. PubMed | CrossRef

Colamaio M, Borbone E, Russo L, Bianco M, et al. miR-191 Down-Regulation Plays a Role in Thyroid Follicular Tumors through CDK6 Targeting. J Clin Endocrinol Metab 2011; 96:E1915–E1924. View Full Text | PubMed | CrossRef

D'Agostino M, Voce P, Celano M, Sponziello M, et al. Sunitinib Exerts Only Limited Effects on the Proliferation and Differentiation of Anaplastic Thyroid Cancer Cells. Thyroid 2012; 22:138–144. PubMed | CrossRef

Derbel O, Limem S, Segura-Ferlay C, Lifante JC, et al. Results of combined treatment of anaplastic thyroid carcinoma (ATC) - art. no. 469. BMC Cancer 2011; 11:1.

Dong XY, Korch C, Meinkoth JL. Histone deacetylase inhibitors upregulate Rap1GAP and inhibit Rap activity in thyroid tumor cells. Endocr-Relat Cancer 2011; 18:301–310. PubMed | CrossRef

Esposito F, Tornincasa M, Pallante P, Federico A, et al. Down-Regulation of the miR-25 and miR-30d Contributes to the Development of Anaplastic Thyroid Carcinoma Targeting the Polycomb Protein EZH2. J Clin Endocrinol Metab 2012; 97:E710–E718.

▪. Foote RL, Molina JR, Kasperbauer JL, et al. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. Thyroid 2011; 21:25–30. [09]

Gholami S, Haddad D, Chen CH, Chen NHG, et al. Novel therapy for anaplastic thyroid carcinoma cells using an oncolytic vaccinia virus carrying the human sodium iodide symporter. Surgery 2011; 150:1040–1046. View Full Text | PubMed | CrossRef

Grant CS, Thompson G. Anaplastic thyroid carcinoma: Hope on the horizon? Surgery 2011; 150:1220–1221.

Harris PJ, Bible KC. Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches. Expert Opin Investig Drugs 2011; 20:1357–1375. PubMed | CrossRef

Hollenbeak CS, Wang L, Schneider P, Goldenberg D. Outcomes of thyroid cancer in african americans. Ethn Dis 2011; 21:210–215. PubMed

Huang LC, Poultsides GA, Norton JA. Surgical Management of Neuroendocrine Tumors of the Gastrointestinal Tract. Oncology-NY 2011; 25:794–803.

▪. Ito K, Hanamura T, Murayama K, et al. Multimodality therapeutic outcomes in anaplastic thyroid carcinoma: improved survival in subgroups of patients with localized primary tumors. Head Neck 2012; 34:230–237. [33]

Ito K, Hanamura T, Murayama K, Okada T, et al. Multimodality therapeutic outcomes In anaplastic thyroid carcinoma: Improved survival in subgroups of patients with localized primary tumors. Head Neck-J Sci Spec Head Neck 2012; 34:230–237.

Kapiteijn E, Schneider TC, Morreau H, Gelderblom H, et al. New treatment modalities in advanced thyroid cancer. Ann Oncol 2012; 23:10–18. View Full Text | PubMed | CrossRef

Kim JE, Ahn BC, Hwang MH, Jeon YH, et al. Combined RNA Interference of Hexokinase II and I-131-Sodium Iodide Symporter Gene Therapy for Anaplastic Thyroid Carcinoma. J Nucl Med 2011; 52:1756–1763. PubMed | CrossRef

Krzeslak A, Jozwiak P, Lipinska A. Down-regulation of beta-N-acetyl-D-glucosaminidase increases Akt1 activity in thyroid anaplastic cancer cells. Oncol Rep 2011; 26:743–749. PubMed

Lassalle S, Hofman V, Ilie M, Bonnetaud C, et al. Can the microRNA signature distinguish between thyroid tumors of uncertain malignant potential and other well-differentiated tumors of the thyroid gland? Endocr-Relat Cancer 2011; 18:579–594.

Lerch C, Richter B. Pharmacotherapy Options for Advanced Thyroid Cancer A Systematic Review. Drugs 2012; 72:67–85. View Full Text | PubMed | CrossRef

▪. Lim SM, Shin SJ, Chung WY, et al. Treatment outcome of patients with anaplastic thyroid cancer: a single center experience. Yonsei Med J 2012; 53:352–357. [08]

Malehmir M, Haghpanah V, Larijani B, Ahmadian S, et al. Multifaceted suppression of aggressive behavior of thyroid carcinoma by all-trans retinoic acid induced re-differentiation. Mol Cell Endocrinol 2012; 348:260–269. PubMed

Misiukiewicz K, Posner M. Time to Change the Treatment Paradigms in Anaplastic Thyroid Carcinoma. Oncology-NY 2012; 26:408–410.

▪. Nagaiah G, Hossain A, Mooney CJ, et al. Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment. J Oncol 2011; 2011:542358. [11]

Nehs MA, Nucera C, Nagarkatti SS, Sadow PM, et al. Late Intervention with anti-BRAF(V600E) Therapy Induces Tumor Regression in an Orthotopic Mouse Model of Human Anaplastic Thyroid Cancer. Endocrinology 2012; 153:985–994. View Full Text | PubMed | CrossRef

Phan T, Yu XM, Kunnimalaiyaan M, Chen H. ASSOCIATION FOR ACADEMIC SURGERY Antiproliferative Effect of Chrysin on Anaplastic Thyroid Cancer. J Surg Res 2011; 170:84–88. PubMed

Rusinek D, Szpak-Ulczok S, Jarzab B. Gene expression profile of human thyroid cancer in relation to its mutational status. J Mol Endocrinol 2011; 47:R91–R103. PubMed | CrossRef

▪. Schoenfeld JD, Odejide OO, Wirth LJ, Chan AW. Survival of a patient with anaplastic thyroid cancer following intensity-modulated radiotherapy and sunitinib – a case report. Anticancer Res 2012; 32:1743–1746. [36]

Schoenfeld JD, Odejide OO, Wirth LJ, Chan AW. Survival of a Patient with Anaplastic Thyroid Cancer Following Intensity-modulated Radiotherapy and Sunitinib - A Case Report. Anticancer Res 2012; 32:1743–1746. PubMed

▪▪. Sherman EJ, Lim SH, Ho AL, et al. Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: a critical re-evaluation including uniform pathologic review. Radiother Oncol 2011; 101:425–430. [10]

Sherman EJ, Lim SH, Ho AL, Ghossein RA, et al. Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: A critical re-evaluation including uniform pathologic review. Radiother Oncol 2011; 101:425–430. PubMed | CrossRef

▪▪. Sosa JA, Elisei R, Jarzab B, et al. A randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): final survival analysis for the FACT trial. J Clin Oncol 2011; 29(Suppl):abstr 5502. [23]

Sugitani I, Miyauchi A, Sugino K, Okamoto T, et al. Prognostic Factors and Treatment Outcomes for Anaplastic Thyroid Carcinoma: ATC Research Consortium of Japan Cohort Study of 677 Patients. World JSurg 2012; 36:1247–1254.

Verburg FA, Brans B, Mottaghy FM. Molecular nuclear therapies for thyroid carcinoma. Methods 2011; 55:230–237. PubMed | CrossRef

Walsh S, Prichard R, Hill ADK. Emerging therapies for thyroid carcinoma. Surg J R Coll Surg Edinb Irel 2012; 10:53–58.

Wunderlich A, Arndt T, Fischer M, Roth S, et al. Targeting the proteasome as a promising therapeutic strategy in thyroid cancer. J Surg Oncol 2012; 105:357–364. View Full Text | PubMed | CrossRef

Zhong WB, Hsu SP, Ho PY, Liang YC, et al. Lovastatin inhibits proliferation of anaplastic thyroid cancer cells through up-regulation of p27 by interfering with the Rho/ROCK-mediated pathway. Biochem Pharmacol 2011; 82: 1663–1672. View Full Text | PubMed | CrossRef

Back to Top | Article Outline
Cancer biology
p21WAF1 and tumourigenesis: 20 years after

Review: (pp. 52–58)

▪. Capparelli C, Chiavarina B, Whitaker-Menezes D, et al. Cdk inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts, ‘fueling’ tumor growth via paracrine interactions, without an increase in neo-angiogenesis. Cell Cycle 2012; 11:3599–3610. [36]

▪▪. Cornils H, Kohler RS, Hergovich A, Hemmings BA. Human ndr kinases control g(1)/s cell cycle transition by directly regulating p21 stability. Mol Cell Biol 2011; 31:1382–1395. [20]

Junker K, Hartmann A, Stockle M. Therapy selection in patients with advanced bladder cancer. Is molecular biology helpful? Urologe 2012A). 51:805–812.

▪. Liu M, Casimiro MC, Wang C, et al. P21cip1 attenuates ras- and c-myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo. Proc Natl Acad Sci U S A 2009; 106:19035–19039. [35]

▪▪. Nie M, Balda MS, Matter K. Stress- and rho-activated zo-1-associated nucleic acid binding protein binding to p21 mRNA mediates stabilization, translation, and cell survival. Proc Natl Acad Sci U S A 2012; 109:10897–10902. [12]

Sanz-Santos J, Andreo F, Castella E, Llatjos M, et al. Representativeness of nodal sampling with endobronchial ultrasonography in non-small-cell lung cancer staging. Ultrasound Med Biol 2012; 38:62–68. PubMed | CrossRef

▪▪. Starostina NG, Simpliciano JM, McGuirk MA, Kipreos ET. Crl2(lrr-1) targets a cdk inhibitor for cell cycle control in c. Elegans and actin-based motility regulation in human cells. Dev Cell 2010; 19:753–764. [16]

▪▪. Viale A, De Franco F, Orleth A, et al. Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells. Nature 2009; 457:51–56. [34]

Back to Top | Article Outline
Lessons from tumor reversion for cancer treatment

Review: (pp. 59–65)

▪. Amson R, Pece S, Lespagnol A, et al. Reciprocal repression between P53 and TCTP. Nat Med 2012; 18:91–99. [13]

▪. Baylot V, Katsogiannou M, Andrieu C, et al. Targeting TCTP as a new therapeutic strategy in castration resistant prostate cancer. Mol Ther 2012. [Epub ahead of print] [46]

▪. Cook N, Frese KK, Bapiro TE, et al. Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. J Exp Med 2012; 209:437–444. [54]

▪. Funston G, Goh W, Wei SJ, et al. Binding of translationally controlled tumour protein to the N-terminal domain of HDM2 is inhibited by Nutlin-3. PLoS One 2012; 7:e42642. [37]

Vincent M. Cancer: A de-repression of a default survival program common to all cells? Bioessays 2012; 34:72–82.

Back to Top | Article Outline
Tumor-cell-derived microvesicles as carriers of molecular information in cancer

Review: (pp. 66–75)

▪. Baietti MF, Zhang Z, Mortier E, et al. Syndecan–syntenin–ALIX regulates the biogenesis of exosomes. Nat Cell Biol 2012; 14:677–685. [11]

Balkwill FR. The chemokine system and cancer. J Pathol 2012; 226:148–157.

Chow KH, Factor RE, Ullman KS. The nuclear envelope environment and its cancer connections. Nat Rev Immunol 2012 Cancer. 12:196–209.

▪. Grange C, Tapparo M, Collino F, et al. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res 2011; 71:5346–5356. [60]

▪▪. Gross JC, Chaudhary V, Bartscherer K, Boutros M. Active Wnt proteins are secreted on exosomes. Nat Cell Biol 2012; 14:1036–1045. [25]

▪▪. Henderson MC, Azorsa DO. The genomic and proteomic content of cancer cell-derived exosomes. Front Oncol 2012; 2:38. [03]

▪▪. Hood J, San R, Wickline S. Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res 2011; 71:3792–3801. [65]

▪. Mathivanan S, Fahner CJ, Reid GE, Simpson RJ. ExoCarta 2012: database of exosomal proteins, RNA and lipids. Nucleic Acids Res 2012; 40:D1241–D1244. [17]

Matsumura Y. Cancer stromal targeting (CAST) therapy. Adv Drug Deliv Rev 2012; 64:710–719. View Full Text | PubMed | CrossRef

▪. Nabhan JF, Hu R, Oh RS, et al. Formation and release of arrestin domain-containing protein 1-mediated microvesicles (ARMMs) at plasma membrane by recruitment of TSG101 protein. Proc Natl Acad Sci USA 2012; 109:4146–4151. [16]

▪▪. Peinado H, Aleckovic M, Lavotshkin S, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 2012; 18:883–891. [45]

▪▪. Peinado H, Lavotshkin S, Lyden D. The secreted factors responsible for premetastatic niche formation: old sayings and new thoughts. Semin Cancer Biol 2011; 21:139–146. [06]

Potter SM, Dwyer RM, Hartmann MC, Khan S, et al. Influence of stromal-epithelial interactions on breast cancer in vitro and in vivo. Breast Cancer Res Treat 2012; 131:401–411. View Full Text | PubMed | CrossRef

Rak J, Guha A. Extracellular vesicles - vehicles that spread cancer genes. Bioessays 2012; 34:489–497.

Santos CI, Costa-Pereira AP. Signal transducers and activators of transcription-from cytokine signalling to cancer biology. Biochim Biophys Acta-Rev Cancer 2011; 1816:38–49. PubMed | CrossRef

Sun XD, Shi XJ, Sun XO, Luo YG, et al. Dimethylenastron suppresses human pancreatic cancer cell migration and invasion in vitro via allosteric inhibition of mitotic kinesin Eg5. Acta Pharmacol Sin 2011; 32:1543–1548. PubMed | CrossRef

Back to Top | Article Outline
TGF-β signaling and epithelial–mesenchymal transition in cancer progression

Review: (pp. 76–84)

Ali NA, Molloy MP. Quantitative phosphoproteomics of transforming growth factor-beta signaling in colon cancer cells. Proteomics 2011; 11:3390–3401. PubMed | CrossRef

▪. Beach JR, Hussey GS, Miller TE, et al. Myosin II isoform switching mediates invasiveness after TGF-β-induced epithelial–mesenchymal transition. Proc Natl Acad Sci USA 2011; 108:17991–17996. [59]

▪. Chaudhury A, Hussey GS, Ray PS, et al. TGF-β-mediated phosphorylation of hnRNP E1 induces EMT via transcript-selective translational induction of Dab2 and ILEI. Nat Cell Biol 2010; 12:286–293. [39]

Chow KH, Factor RE, Ullman KS. The nuclear envelope environment and its cancer connections. Nat Rev Immunol 2012 Cancer. 12:196–209.

▪. Dong C, Wu Y, Yao J, et al. G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer. J Clin Invest 2012; 122:1469–1486. [31]

▪. Eckert MA, Lwin TM, Chang AT, et al. Twist1-induced invadopodia formation promotes tumor metastasis. Cancer Cell 2011; 19:372–386. [55]

▪. Ezponda T, Popovic R, Shah MY, et al. The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial–mesenchymal transition and invasive properties of prostate cancer. Oncogene 2012. [28]

▪▪. Giampieri S, Manning C, Hooper S, et al. Localized and reversible TGFβ signalling switches breast cancer cells from cohesive to single cell motility. Nat Cell Biol 2009; 11:1287–1296. [54]

▪. Horiguchi K, Sakamoto K, Koinuma D, et al. TGF-β drives epithelial–mesenchymal transition through deltaEF1-mediated downregulation of ESRP. Oncogene 2012; 31:3190–3201. [25]

▪. Hussey GS, Chaudhury A, Dawson AE, et al. Identification of an mRNP complex regulating tumorigenesis at the translational elongation step. Mol Cell 2011; 41:419–431. [40]

▪. Lamouille S, Connolly E, Smyth JW, et al. TGF-β-induced activation of mTOR complex 2 drives epithelial–mesenchymal transition and cell invasion. J Cell Sci 2012; 125:1259–1273. [38]

▪. Pignatelli J, Tumbarello DA, Schmidt RP, Turner CE. Hic-5 promotes invadopodia formation and invasion during TGF-β-induced epithelial–mesenchymal transition. J Cell Biol 2012; 197:421–437. [58]

▪▪. Ricci-Vitiani L, Pallini R, Biffoni M, et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010; 468:824–828. [78]

▪▪. Scheel C, Eaton EN, Li SH, et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 2011; 145:926–940. [48]

Schroten C, Dits NF, Steyerberg EW, Kranse R, et al. The additional value of TGF beta 1 and IL-7 to predict the course of prostate cancer progression. Cancer Immunol Immunother 2012; 61:905–910. PubMed | CrossRef

▪. Shirakihara T, Horiguchi K, Miyazawa K, et al. TGF-β regulates isoform switching of FGF receptors and epithelial–mesenchymal transition. EMBO J 2011; 30:783–795. [26]

▪. Subramanyam D, Lamouille S, Judson RL, et al. Multiple targets of miR-302 and miR-372 promote reprogramming of human fibroblasts to induced pluripotent stem cells. Nat Biotechnol 2011; 29:443–448. [34]

▪▪. Wang R, Chadalavada K, Wilshire J, et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010; 468:829–833. [79]

Back to Top | Article Outline
Interactions between the tumor suppressor p53 and immune responses

Review: (pp. 85–92)

▪▪. Frank AK, Leu JI, Zhou Y, et al. The codon 72 polymorphism of p53 regulates interaction with NF-kB and transactivation of genes involved in immunity and inflammation. Mol Cell Biol 2011; 31:1201–1213. [43]

▪▪. Goutagny N, Estornes Y, Hasan U, et al. Targeting pattern recognition receptors in cancer immunotherapy. Target Oncol 2012; 7:29–54. [69]

▪▪. Munoz-Fontela C, Pazos M, Delgado I, et al. p53 serves as a host antiviral factor that enhances innate and adaptive immune responses to influenza A virus. J Immunol 2011; 187:6428–6436. [38]

Polakis P. Drugging Wnt signalling in cancer. Embo J 2012; 31:2737–2746. PubMed | CrossRef

▪▪. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331:1565–1570. [03]

▪. Shatz M, Menendez D, Resnick MA. The human TLR innate immune gene family is differentially influenced by DNA stress and p53 status in cancer cells. Cancer Res 2012. [Epub ahead of Print]. [07]

Back to Top | Article Outline
Sowing the seeds of cancer: telomeres and age-associated tumorigenesis

Review: (pp. 93–98)

Ahmad I, Patel R, Singh LB, Nixon C, et al. HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer. Proc Natl Acad Sci U S A 2011; 108:16392–16397. PubMed | CrossRef

Azad A, Jackson S, Cullinane C, Natoli A, et al. Inhibition of DNA-Dependent Protein Kinase Induces Accelerated Senescence in Irradiated Human Cancer Cells. Mol Cancer Res 2011; 9:1696–1707.

▪▪. Baker DJ, Wijshake T, Tchkonia T, et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature 2011; 479:232–236. [37]

▪. Bernardes de Jesus B, Vera E, Schneeberger K, et al. Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer. EMBO Mol Med 2012; 4:691–704. [47]

▪▪. Davoli T, de Lange T. Telomere-driven tetraploidization occurs in human cells undergoing crisis and promotes transformation of mouse cells. Cancer Cell 2012; 21:765–776. [23]

▪. De Jesus BB, Schneeberger K, Vera E, et al. The telomerase activator TA-65 elongates short telomeres and increases health span of adult/old mice without increasing cancer incidence. Aging Cell 2011; 10:604–621. [46]

▪▪. Ding Z, Wu CJ, Jaskelioff M, et al. Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell 2012; 148:896–907. [27]

▪. Fumagalli M, Rossiello F, Clerici M, et al. Telomeric DNA damage is irreparable and causes persistent DNA-damage-response activation. Nat Cell Biol 2012; 14:355–365. [12]

▪. Hewitt G, Jurk D, Marques FD, et al. Telomeres are favoured targets of a persistent DNA damage response in ageing and stress-induced senescence. Nat Commun 2012; 3:708. [13]

Jones AM, Beggs AD, Carvajal-Carmona L, Farrington S, et al. TERC polymorphisms are associated both with susceptibility to colorectal cancer and with longer telomeres. Gut 2012; 61:248–254. View Full Text | PubMed | CrossRef

Li WW, Yu JY, Xu HL, Bao JK. Concanavalin A: A potential anti-neoplastic agent targeting apoptosis, autophagy and anti-angiogenesis for cancer therapeutics. Biochem Biophys Res Commun 2011; 414:282–286.

Melin BS, Nordfjall K, Andersson U, Roos G. hTERT Cancer Risk Genotypes Are Associated With Telomere Length. Genet Epidemiol 2012; 36:368–372. PubMed | CrossRef

Mieog JSD, de Kruijf EM, Bastiaannet E, Kuppen PJK, et al. Age determines the prognostic role of the cancer stem cell marker aldehyde dehydrogenase-1 in breast cancer - art. no. 42. BMC Cancer 2012; 12:26.

▪. Rodier F, Munoz DP, Teachenor R, et al. DNA-SCARS: distinct nuclear structures that sustain damage-induced senescence growth arrest and inflammatory cytokine secretion. J Cell Sci 2011; 124:68–81. [33]

▪. Sahin E, Colla S, Liesa M, et al. Telomere dysfunction induces metabolic and mitochondrial compromise. Nature 2011; 470:359–365. [20]

Sand-Dejmek J, Adelmant G, Sobhian B, Calkins AS, et al. Concordant and opposite roles of DNA-PK and the ‘‘facilitator of chromatin transcription’' (FACT) in DNA repair, apoptosis and necrosis after cisplatin - art. no. 74. Mol Cancer 2011; 10:16.

▪▪. Suram A, Kaplunov J, Patel PL, et al. Oncogene-induced telomere dysfunction enforces cellular senescence in human cancer precursor lesions. EMBO J 2012; 31:2839–2851. [11]

Vicente-Duenas C, Romero-Camarero I, Sanchez-Garcia I. Understanding telomerase in cancer stem cell biology. Cell Cycle 2012; 11:1479–1480. PubMed | CrossRef

Back to Top | Article Outline
The PI3 Kinase/mTOR pathway in growth control, inflammation and metabolism

Boyault S, Drouet Y, Navarro C, Bachelot T, et al. Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes. Breast Cancer Res Treat 2012; 132:29–39. View Full Text | PubMed | CrossRef

Certal V, Halley F, Virone-Oddos A, Delorme C, et al. Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3K beta Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers. J Med Chem 2012; 55: 4788–4805. PubMed | CrossRef

Cohen Y, Goldenberg-Cohen N, Shalmon B, Shani T, et al. Mutational analysis of PTEN/PIK3CA/AKT pathway in oral squamous cell carcinoma. Eur J Cancer 2011 Part B, Oral Oncology. 47:946-950.

Honig A, Hahne JC, Meyer S, Kranke P, et al. PI3K Inhibitor D-116883 is Effective in In Vitro Models of Ovarian Cancer. Anticancer Res 2012; 32:2035–2041. PubMed

Kampen KR. The mechanisms that regulate the localization and overexpression of VEGF receptor-2 are promising therapeutic targets in cancer biology. Anti-Cancer Drugs 2012; 23:347–354.

Kinross KM, Montgomery KG, Kleinschmidt M, Waring P, et al. An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. J Clin Invest 2012; 122:553–557. View Full Text | PubMed | CrossRef

Kudo Y, Tanaka Y, Tateishi K, Yamamoto K, et al. Altered composition of fatty acids exacerbates hepatotumorigenesis during activation of the phosphatidylinositol 3-kinase pathway. J Hepatol 2011; 55:1400–1408. PubMed | CrossRef

Laronga C, Harness JK, Dixon M, Borgen PI. The role of the breast cancer surgeon in personalized cancer care: clinical utility of the 21-gene assay. Am J Surg 2012; 203:751–758. PubMed | CrossRef

Wang HN, Liu H, Chen KY, Xiao JF, et al. SIRT1 promotes tumorigenesis of hepatocellular carcinoma through PI3K/PTEN/AKT signaling. Oncol Rep 2012; 28:311–318. PubMed

Wang LE, Ma HX, Hale KS, Yin M, et al. Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes. J Cancer Res Clin Oncol 2012; 138:377–385. PubMed | CrossRef

Wullschleger S, Garcia-Martinez JM, Duce SL. Quantitative MRI Establishes the Efficacy of PI3K Inhibitor (GDC-0941) Multi-Treatments in PTEN-deficient Mice Lymphoma. Anticancer Res 2012; 32:415–420. PubMed

Zha XJ, Hu ZD, He SZ, Wang F, et al. TSC1/TSC2 inactivation inhibits AKT through mTORC1-dependent up-regulation of STAT3-PTEN cascade. Cancer Lett 2011; 313:211–217. PubMed | CrossRef

Back to Top | Article Outline
PTEN in the control of tumorigenesis

Ahmad I, Patel R, Singh LB, Nixon C, et al. HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer. Proc Natl Acad Sci U S A 2011; 108:16392–16397. PubMed | CrossRef

Barber DL. GRPling with PTEN. Blood 2012; 119:648–649. PubMed | CrossRef

Bloomekatz J, Grego-Bessa J, Migeotte I, Anderson KV. Pten regulates collective cell migration during specification of the anterior-posterior axis of the mouse embryo. Dev Biol 2012; 364:192–201. PubMed

Byun DS, Ahmed N, Nasser S, Shin J, et al. Intestinal epithelial-specific PTEN inactivation results in tumor formation. Am J Physiol-Gastroint Liver Physiol 2011; 301:G856–G864.

Certal V, Halley F, Virone-Oddos A, Delorme C, et al. Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3K beta Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers. J Med Chem 2012; 55: 4788–4805. PubMed | CrossRef

Chen HB, Mei L, Zhou LZ, Shen XM, et al. PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts. J Neuro-Oncol 2011; 104:155–167. PubMed | CrossRef

Chetram MA, Don-Salu-Hewage AS, Hinton CV. ROS enhances CXCR4-mediated functions through inactivation of PTEN in prostate cancer cells. Biochem Biophys Res Commun 2011; 410:195–200. PubMed | CrossRef

Cohen Y, Goldenberg-Cohen N, Shalmon B, Shani T, et al. Mutational analysis of PTEN/PIK3CA/AKT pathway in oral squamous cell carcinoma. Eur J Cancer 2011 Part B, Oral Oncology. 47:946–950.

Darido C, Georgy SR, Wilanowski T, Dworkin S, et al. Targeting of the Tumor Suppressor GRHL3 by a miR-21-Dependent Proto-Oncogenic Network Results in PTEN Loss and Tumorigenesis. Cancer Cell 2011; 20:635–648. PubMed | CrossRef

Fu X, Tian J, Zhang L, Chen Y, et al. Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells. FEBS Lett 2012; 586:1279–1286. PubMed | CrossRef

Huang WJ, Lin CW, Lee CY, Chi LL, et al. NBM-HD-3, a novel histone deacetylase inhibitor with anticancer activity through modulation of PTEN and AKT in brain cancer cells. J Ethnopharmacol 2011; 136:156–167. PubMed | CrossRef

Ioffe YJ, Chiappinelli KB, Mutch DG, Zighelboim I, et al. Phosphatase and tensin homolog (PTEN) pseudogene expression in endometrial cancer: a conserved regulatory mechanism important in tumorigenesis? Gynecol Oncol 2012; 124:340–346.

Karreth FA, Tay Y, Perna D, Ala U, et al. In Vivo Identification of Tumor-Suppressive PTEN ceRNAs in an Oncogenic BRAF-Induced Mouse Model of Melanoma. Cell 2011; 147:382–395. PubMed | CrossRef

Kim J, Roh M, Doubinskaia I, Algarroba GN, et al. A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53. Oncogene 2012; 31:322–332. View Full Text | PubMed | CrossRef

Svensson RU, Haverkamp JM, Thedens DR, Cohen MB, et al. Slow Disease Progression in a C57BL/6 Pten-Deficient Mouse Model of Prostate Cancer. Am J Pathol 2011; 179:502–512. PubMed | CrossRef

Tay Y, Kats L, Salmena L, Weiss D, et al. Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs. Cell 2011; 147:344–357. PubMed | CrossRef

Wang YY, Wang XF, Zhang JX, Sun G, et al. MicroRNAs involved in the EGFR/PTEN/AKT pathway in gliomas. J Neuro-Oncol 2012; 106:217–224. PubMed

Wullschleger S, Garcia-Martinez JM, Duce SL. Quantitative MRI Establishes the Efficacy of PI3K Inhibitor (GDC-0941) Multi-Treatments in PTEN-deficient Mice Lymphoma. Anticancer Res 2012; 32:415–420. PubMed

Xu PZ, Chen ML, Jeon SM, Peng XD, et al. The effect Akt2 deletion on tumor development in Pten(+/-) mice. Oncogene 2012; 31:518–526. View Full Text | PubMed | CrossRef

Zha XJ, Hu ZD, He SZ, Wang F, et al. TSC1/TSC2 inactivation inhibits AKT through mTORC1-dependent up-regulation of STAT3-PTEN cascade. Cancer Lett 2011; 313:211–217. PubMed | CrossRef

Back to Top | Article Outline
E2F1/p53 regulatory loops in growth control and cancer

Boyault S, Drouet Y, Navarro C, Bachelot T, et al. Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes. Breast Cancer Res Treat 2012; 132:29–39. View Full Text | PubMed | CrossRef

Jiang JH, Yang ES, Jiang GC, Nowsheen S, et al. p53-Dependent BRCA1 Nuclear Export Controls Cellular Susceptibility to DNA Damage. Cancer Res 2011; 71:5546–5557. PubMed | CrossRef

Nguyen D, Zajac-Kaye M, Rubinstein L, Voeller D, et al. Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent. Cell Cycle 2011; 10:4074–4082. PubMed | CrossRef

Otto N, Schulz P, Scholz A, Hauff P, et al. The proline TP53 variant stimulates likely lymphangiogenesis in an orthotopic mouse model of pancreatic cancer. Br J Cancer 2012; 106:348–357. PubMed | CrossRef

Back to Top | Article Outline
Targeting angiogenesis

Bar J, Goss GD. Tumor Vasculature as a Therapeutic Target in Non-small Cell Lung Cancer. J Thorac Oncol 2012; 7:609–620. View Full Text | PubMed

Belotti D, Foglieni C, Resovi A, Giavazzi R, et al. Targeting angiogenesis with compounds from the extracellular matrix. Int J Biochem Cell Biol 2011; 43:1674–1685. PubMed | CrossRef

Bid HK, Zhan J, Phelps DA, Kurmasheva RT, et al. Potent Inhibition of Angiogenesis by the IGF-1 Receptor-Targeting Antibody SCH717454 Is Reversed by IGF-2. Mol Cancer Ther 2012; 11:649–659. PubMed | CrossRef

Bottos A, Martini M, Di Nicolantonio F, Comunanza V, et al. Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia. Proc Natl Acad Sci U S A 2012; 109:E353–E359. PubMed | CrossRef

Chen CT, Yamaguchi H, Lee HJ, Du Y, et al. Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin-Cytosine Deaminase-Uracil Phosphoribosyltransferase. Mol Cancer Ther 2011; 10:1327–1336. PubMed | CrossRef

Chen HJ, Fan KC, Wang SS, Liu Z, et al. Dual Targeting of Glioma U251 Cells with Nanoparticles Prevents Tumor Angiogenesis and Inhibits Tumor Growth. Curr Neurovasc Res 2012; 9:133–138. View Full Text | PubMed | CrossRef

Christopoulos A, Ahn SM, Klein JD, Kim S. Biology of vascular endothelial growth factor and its receptors in head and neck cancer: beyond angiogenesis. Head Neck-J Sci Spec Head Neck 2011; 33:1220–1229.

de Oliveira RL, Hamm A, Mazzone M. Growing tumor vessels: More than one way to skin a cat - Implications for angiogenesis targeted cancer therapies. Mol Asp Med 2011; 32:71–87. PubMed | CrossRef

Di Paolo D, Ambrogio C, Pastorino F, Brignole C, et al. Selective Therapeutic Targeting of the Anaplastic Lymphoma Kinase With Liposomal siRNA Induces Apoptosis and Inhibits Angiogenesis in Neuroblastoma. Mol Ther 2011; 19:2201–2212. PubMed | CrossRef

Halkia E, Kalinoglou N. Challenges with identification of angiogenesis biomarkers in cancer. Surg Endosc 2011; 25:2769–2770. PubMed | CrossRef

Ichihara E, Kiura K, Tanimoto M. Targeting Angiogenesis in Cancer Therapy. Acta Med Okayama 2011; 65:353–362. PubMed

Kamisasanuki T, Tokushige S, Terasaki H, Khai NC, et al. Targeting CD9 produces stimulus-independent antiangiogenic effects predominantly in activated endothelial cells during angiogenesis: A novel antiangiogenic therapy. Biochem Biophys Res Commun 2011; 413:128–135.

Kampen KR. The mechanisms that regulate the localization and overexpression of VEGF receptor-2 are promising therapeutic targets in cancer biology. Anti-Cancer Drugs 2012; 23:347–354.

Kim JY, Shim G, Choi HW, Park J, et al. Tumor vasculature targeting following co-delivery of heparin-taurocholate conjugate and suberoylanilide hydroxamic acid using cationic nanolipoplex. Biomaterials 2012; 33:4424–4430. PubMed | CrossRef

Klotz LV, Eichhorn ME, Schwarz B, Seeliger H, et al. Targeting the vasculature of visceral tumors: novel insights and treatment perspectives. Langenbecks Arch Surg 2012; 397:569–578. PubMed | CrossRef

Li WW, Yu JY, Xu HL, Bao JK. Concanavalin A: A potential anti-neoplastic agent targeting apoptosis, autophagy and anti-angiogenesis for cancer therapeutics. Biochem Biophys Res Commun 2011; 414:282–286.

Linkous AG, Yazlovitskaya EM. Novel Therapeutic Approaches for Targeting Tumor Angiogenesis. Anticancer Res 2012; 32:1–12. PubMed

Liu J, Matulonis UA. Anti-angiogenic Agents in Ovarian Cancer: Dawn of a New Era? Curr Oncol Rep 2011; 13:450–458.

Liu YQ, Li YS, Xu YH. Inhibitory effects of novel integrin-targeting peptides on angiogenesis activity in HUVEC cells in vitro. Cell Biochem Funct 2011; 29:429–435. PubMed

Liu ZJ, Tian RX, Li Y, An WJ, et al. Inhibition of Tumor Angiogenesis and Melanoma Growth by Targeting Vascular E-Selectin. Ann Surg 2011; 254:450–457. View Full Text | PubMed | CrossRef

Ranieri G. Targeting Tumor Angiogenesis: An Update. Curr Med Chem 2012; 19:937. PubMed | CrossRef

Reubi JC, Fleischmann A, Waser B, Rehmann R. Concomitant vascular GRP-receptor and VEGF-receptor expression in human tumors: Molecular basis for dual targeting of tumoral vasculature. Peptides 2011; 32:1457–1462. View Full Text | PubMed | CrossRef

Salva E, Kabasakal L, Eren F, Ozkan N, et al. Local Delivery of Chitosan/VEGF siRNA Nanoplexes Reduces Angiogenesis and Growth of Breast Cancer In Vivo. Nucl Acid Ther 2012; 22:40–48.

Santos ES, Gomez JE, Raez LE. Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor. Invest New Drugs 2012; 30:1261–1269. View Full Text | PubMed | CrossRef

Schmitt J, Matei D. Targeting angiogenesis in ovarian cancer. Cancer Treat Rev 2012; 38:272–283. PubMed | CrossRef

Taeger J, Moser C, Hellerbrand C, Mycielska ME, et al. Targeting FGFR/PDGFR/VEGFR Impairs Tumor Growth, Angiogenesis, and Metastasis by Effects on Tumor Cells, Endothelial Cells, and Pericytes in Pancreatic Cancer. Mol Cancer Ther 2011; 10:2157–2167. PubMed | CrossRef

Thompson SK. Targeting Angiogenesis in Gastroesophageal Cancer: Industry-Sponsored Trials are not the Answer. World JSurg 2012; 36:118–119.

Urbich C, Kaluza D, Fromel T, Knau A, et al. MicroRNA-27a/b controls endothelial cell repulsion and angiogenesis by targeting semaphorin 6A. Blood 2012; 119:1607–1616. PubMed | CrossRef

Wang SJ, Sun B, Cheng ZX, Zhou HX, et al. Dihydroartemisinin inhibits angiogenesis in pancreatic cancer by targeting the NF-kappa B pathway. Cancer Chemother Pharmacol 2011; 68:1421–1430.

Watari K, Nakamura M, Fukunaga Y, Furuno A, et al. The antitumor effect of a novel angiogenesis inhibitor (an octahydronaphthalene derivative) targeting both VEGF receptor and NF-kappa B pathway. Int J Cancer 2012; 131:310–321. PubMed | CrossRef

Weiss A, van den Bergh H, Griffioen AW, Nowalk-Sliwinska P. Angiogenesis inhibition for the improvement of photodynamic therapy: The revival of a promising idea. Biochim Biophys Acta-Rev Cancer 2012; 1826:53–70. PubMed | CrossRef

Wu YY, He LJ, Zhang L, Chen J, et al. Anacardic Acid (6-Pentadecylsalicylic Acid) Inhibits Tumor Angiogenesis by Targeting Src/FAK/Rho GTPases Signaling Pathway. J Pharmacol Exp Ther 2011; 339:403–411. PubMed | CrossRef

Zand B, Coleman RL, Sood AK. Targeting Angiogenesis in Gynecologic Cancers. Hematol Oncol Clin North Am 2012; 26:543. PubMed | CrossRef

Zhang SX, Zhu C, Ba Y, Chen D, et al. Gekko-sulfated Glycopeptide Inhibits Tumor Angiogenesis by Targeting Basic Fibroblast Growth Factor. J Biol Chem 2012; 287: 13206–13215. PubMed | CrossRef

Back to Top | Article Outline
Targeting mutant p53 through the mevalonate pathway

Boyault S, Drouet Y, Navarro C, Bachelot T, et al. Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes. Breast Cancer Res Treat 2012; 132:29–39. View Full Text | PubMed | CrossRef

Chen MH, Pratt CP, Zeeman ME, Schultz N, et al. Identification of PHLPP1 as a Tumor Suppressor Reveals the Role of Feedback Activation in PTEN-Mutant Prostate Cancer Progression. Cancer Cell 2011; 20:173–186. PubMed | CrossRef

Darido C, Georgy SR, Wilanowski T, Dworkin S, et al. Targeting of the Tumor Suppressor GRHL3 by a miR-21-Dependent Proto-Oncogenic Network Results in PTEN Loss and Tumorigenesis. Cancer Cell 2011; 20:635–648. PubMed | CrossRef

Jamaly S, Khanehkenari MR, Rao R, Patil G, et al. Relationship between p53 overexpression, human papillomavirus infection, and lifestyle in Indian patients with head and neck cancers. Tumor Biol 2012; 33:543–550. PubMed | CrossRef

Kim J, Roh M, Doubinskaia I, Algarroba GN, et al. A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53. Oncogene 2012; 31:322–332. View Full Text | PubMed | CrossRef

Ma QLC, Ennis CA, Aparicio S. Opening Pandora's Box - the new biology of driver mutations and clonal evolution in cancer as revealed by next generation sequencing. Curr Opin Genet Dev 2012; 22:3–9. PubMed

Ni Y, He X, Chen J, Moline J, et al. Germline SDHx variants modify breast and thyroid cancer risks in Cowden and Cowden-like syndrome via FAD/NAD-dependant destabilization of p53. Hum Mol Genet 2012; 21:300–310.

Ramanathan V, Jin GC, Westphalen CB, Whelan A, et al. P53 Gene Mutation Increases Progastrin Dependent Colonic Proliferation and Colon Cancer Formation in Mice. Cancer Invest 2012; 30:275–286. PubMed | CrossRef

Zha XJ, Hu ZD, He SZ, Wang F, et al. TSC1/TSC2 inactivation inhibits AKT through mTORC1-dependent up-regulation of STAT3-PTEN cascade. Cancer Lett 2011; 313:211–217. PubMed | CrossRef

Back to Top | Article Outline
Targeting DNA repair mechanisms for cancer treatment

Abbasi R, Efferth T, Kuhmann C, Opatz T, et al. The endoperoxide ascaridol shows strong differential cytotoxicity in nucleotide excision repair-deficient cells. Toxicol Appl Pharmacol 2012; 259:302–310. View Full Text | PubMed

Aziz K, Nowsheen S, Pantelias G, Iliakis G, et al. Targeting DNA damage and repair: Embracing the pharmacological era for successful cancer therapy. Pharmacol Ther 2012; 133:334–350. View Full Text | PubMed | CrossRef

Dong XQ, Li YA, Chang P, Hess KR, et al. DNA mismatch repair network gene polymorphism as a susceptibility factor for pancreatic cancer. Mol Carcinog 2012; 51:491–499. View Full Text | PubMed | CrossRef

Feng ZZ, Chen JW, Yang ZR, Lu GZ, et al. Expression of PTTG1 and PTEN in endometrial carcinoma: correlation with tumorigenesis and progression. Med Oncol 2012; 29:304–310. PubMed | CrossRef

Hamer PCD, Mir SE, Noske D, Van Noorden CJF, et al. WEE1 Kinase Targeting Combined with DNA-Damaging Cancer Therapy Catalyzes Mitotic Catastrophe. Clin Cancer Res 2011; 17:4200–4207. PubMed

Nguyen D, Zajac-Kaye M, Rubinstein L, Voeller D, et al. Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent. Cell Cycle 2011; 10:4074–4082. PubMed | CrossRef

Nowsheen S, Whitley AC, Yang ES. Biomarkers to Assess the Targeting of DNA Repair Pathways to Augment Tumor Response to Therapy. Curr Mol Med 2012; 12:788–803. PubMed | CrossRef

Paul I, Savage KI, Blayney JK, Lamers E, et al. PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer. J Pathol 2011; 224:564–574. View Full Text | PubMed | CrossRef

Sand-Dejmek J, Adelmant G, Sobhian B, Calkins AS, et al. Concordant and opposite roles of DNA-PK and the ‘‘facilitator of chromatin transcription’' (FACT) in DNA repair, apoptosis and necrosis after cisplatin - art. no. 74. Mol Cancer 2011; 10:16.

Sato A, Sunayama J, Matsuda K, Seino S, et al. MEK-ERK Signaling Dictates DNA-Repair Gene MGMT Expression and Temozolomide Resistance of Stem-Like Glioblastoma Cells via the MDM2-p53 Axis. Stem Cells 2011; 29:1942–1951. PubMed | CrossRef

Sillars-Hardebol AH, Carvalho B, Belien JA, de Wit M, et al. BCL2L1 has a functional role in colorectal cancer and its protein expression is associated with chromosome 20q gain. J Pathol 2012; 226:442–450. View Full Text | PubMed | CrossRef

Tobin LA, Robert C, Nagaria P, Chumsri S, et al. Targeting Abnormal DNA Repair in Therapy-Resistant Breast Cancers. Mol Cancer Res 2012; 10:96–107. PubMed | CrossRef

Xue X, You S, Zhang Q, Wu Y, et al. Mitaplatin Increases Sensitivity of Tumor Cells to Cisplatin by Inducing Mitochondrial Dysfunction. Mol Pharm 2012; 9:634–644. PubMed

Zha XJ, Hu ZD, He SZ, Wang F, et al. TSC1/TSC2 inactivation inhibits AKT through mTORC1-dependent up-regulation of STAT3-PTEN cascade. Cancer Lett 2011; 313:211–217. PubMed | CrossRef

© 2013 Lippincott Williams & Wilkins, Inc.

Login